A “real-world” analysis of millions of patient self-reported treatment records from a migraine smartphone app compares the efficacy of acute migraine medications.
In the 18-month trial, people in the early stages of Alzheimer’s who received infusions of donanemab showed 35% less decline in thinking skills compared to those given a dummy drug.
The RESTORE Network is working with a specialized group of experts on clinical trials, testing new therapies and technologies to improve the quality of life for those with neurological disorders.